Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xeloda capecitabine: Phase II data; sNDA under review; marketed to treat metastatic breast cancer

Roche published in the Journal of Clinical Oncology that in

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE